Viral Vector-Based Personalized Cancer Vaccine: Current Mechanisms, Clinical Evidence and Future Directions

Yuqing Zhang

doi:10.54097/8tcvmg95

Authors

Yuqing Zhang

DOI:

https://doi.org/10.54097/8tcvmg95

Keywords:

Personalized Cancer Vaccine, Viral vector, Neoantigen, Immunotherapy.

Abstract

Cancer immunotherapy has become a more popular method to treat cancer. It uses patients’ own immune system to recognize and eliminate cancer cells. Within the different forms of immunotherapy, personalized cancer vaccines (PCVs) stand out as a revolutionary option as they target individual-specific neoantigens. This allows for precise interventions that can trigger long-term immune responses. PCVs are usually developed using three major platforms: mRNA, DNA, and viral vector vaccines. This review focuses on the viral vector strategies, with representative examples of NOUS-PEV, GRANITE, and TG4050. Viral vector vaccines are very good at delivering antigens effectively, trigger strong immune response, and activate both innate and adaptive immunity, leading to strong CD8+ and CD4+ T cell responses. Early clinical trials have shown encouraging safety and immunogenicity, as well as signals of efficacy across different tumor types. However, there are still obstacles remaining. This includes limited accuracy of neoantigen prediction, complex manufacturing process, and tumor-mediated immunosuppression. Future progress is likely going to rely on multi-omics integration, AI-driven epitope prioritization, innovative delivery platforms, and combination strategies with other immunotherapies. Collectively, PCVs have the potential to become the cornerstone of precision oncology to provide personalized and durable therapeutic benefits to cancer patients.

Downloads

Download data is not yet available.

References

[1] Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges and prospects. Signal Transduct Target Ther. 2023 Dec 13;8(1): 450.

[2] Seclì L, Leoni G, Ruzza V, Siani L, Cotugno G, Scarselli E, et al. Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer. Int J Mol Sci. 2023 Jan;24(23): 16591.

[3] Tang J, Amin MA, Campian JL. Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review. Vaccines. 2025 May; 13(5): 524.

[4] Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022 Mar 18; 15(1): 28.

[5] Sampson AT, Hlaváč M, Gillman ACT, Douradinha B, Gilbert SC. Developing the next-generation of adenoviral vector vaccines. Hum Vaccines Immunother. 2025 July; 21(1): 2514356.

[6] Huang KCY, Lai CY, Hung WZ, Chang HY, Lin PC, Chiang SF, et al. A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors. Cancer Immunol Res. 2023 Jan 3; 11(1): 123–36.

[7] Atay C, Medina-Echeverz J, Hochrein H, Suter M, Hinterberger M. Chapter Three - Armored modified vaccinia Ankara in cancer immunotherapy. In: Aranda F, Berraondo P, Galluzzi L, editors. International Review of Cell and Molecular Biology [Internet]. Academic Press; 2023 [cited 2025 Sept 18]. p. 87–142. (Viral Vectors in Cancer Immunotherapy; vol. 379). Available from: https://www.sciencedirect.com/science/article/pii/S1937644823000655

[8] D’Alise AM, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, et al. Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses. Clin Cancer Res Off J Am Assoc Cancer Res. 2024 June 3; 30(11): 2412–23.

[9] Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 July; 547(7662): 217–21.

[10] Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022 Aug; 28(8): 1619–29.

[11] Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science. 2018 Mar 23; 359(6382): 1355–60.

[12] Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014 Nov; 515(7528): 572–6.

[13] Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021 Apr; 18(4): 215–29.

[14] Gritstone bio, Inc. An international phase 1/2 study of GRT-C901/GRT-R902, a neoantigen cancer vaccine, in combination with immune checkpoint blockade for patients with advanced solid tumors. [Internet]. clinicaltrials.gov; 2023 Sept [cited 2025 Sept 18]. Report No.: NCT03639714. Available from: https://clinicaltrials.gov/study/NCT03639714

[15] Volz A, Sutter G. Chapter Five - Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development. In: Kielian M, Mettenleiter TC, Roossinck MJ, editors. Advances in Virus Research [Internet]. Academic Press; 2017 [cited 2025 Sept 18]. p. 187–243. Available from: https://www.sciencedirect.com/science/article/pii/S0065352716300380

[16] Transgene. TG4050 therapeutic vaccine in patients with HPV negative head and neck squamous cell carcinoma [Internet]. clinicaltrials.gov; 2025 June [cited 2025 Sept 18]. Report No.: NCT04183166. Available from: https://clinicaltrials.gov/study/NCT04183166

[17] Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018 Mar; 18(3): 168–82.

[18] Shemesh CS, Hsu JC, Hosseini I, Shen BQ, Rotte A, Twomey P, et al. Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities. Mol Ther. 2021 Feb 3; 29(2): 555–70.

[19] Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017 July; 547 (7662): 222–6.

[20] Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr; 17(4): 261–79.